{"title":"调查未确诊的G3期慢性肾脏疾病全球患病率的REVEAL-CKD研究的发现和意义","authors":"N. Tangri, L. De Nicola","doi":"10.33590/emj/10063690","DOIUrl":null,"url":null,"abstract":"Chronic kidney disease (CKD) is a progressive condition that can lead to \nkidney failure and the requirement for renal dialysis or transplantation. Early-stage \nCKD is often missed because the disorder is initially asymptomatic; hence, many \npatients with CKD already have symptomatic advanced disease (Stages G4–G5) \nat the time of diagnosis. This is an important issue because the drugs available \nfor the treatment of CKD are most effective when given during the early stages of \nthe disease (Stages G1–G3). EMJ conducted interviews in July 2022 with two key \nopinion leaders, Navdeep Tangri from the University of Manitoba, Winnipeg, Canada, \nand Luca De Nicola from the University of Campania Luigi Vanvitell, Naples, Italy, \nboth of whom have a wealth of experience in the management of patients with CKD. \nThe experts provided important insights into the ongoing REVEAL-CKD study, which \nwas designed to explore the global prevalence of undiagnosed Stage G3 CKD. This \narticle describes the main findings of the REVEAL-CKD study published to date and \ntheir implications. Possible approaches to improving the diagnosis of CKD are \nalso discussed.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"38 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Findings and Implications of the REVEAL-CKD Study Investigating the Global Prevalence of Undiagnosed Stage G3 Chronic Kidney Disease\",\"authors\":\"N. Tangri, L. De Nicola\",\"doi\":\"10.33590/emj/10063690\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic kidney disease (CKD) is a progressive condition that can lead to \\nkidney failure and the requirement for renal dialysis or transplantation. Early-stage \\nCKD is often missed because the disorder is initially asymptomatic; hence, many \\npatients with CKD already have symptomatic advanced disease (Stages G4–G5) \\nat the time of diagnosis. This is an important issue because the drugs available \\nfor the treatment of CKD are most effective when given during the early stages of \\nthe disease (Stages G1–G3). EMJ conducted interviews in July 2022 with two key \\nopinion leaders, Navdeep Tangri from the University of Manitoba, Winnipeg, Canada, \\nand Luca De Nicola from the University of Campania Luigi Vanvitell, Naples, Italy, \\nboth of whom have a wealth of experience in the management of patients with CKD. \\nThe experts provided important insights into the ongoing REVEAL-CKD study, which \\nwas designed to explore the global prevalence of undiagnosed Stage G3 CKD. This \\narticle describes the main findings of the REVEAL-CKD study published to date and \\ntheir implications. Possible approaches to improving the diagnosis of CKD are \\nalso discussed.\",\"PeriodicalId\":90162,\"journal\":{\"name\":\"European medical Journal. Urology\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European medical Journal. Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emj/10063690\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European medical Journal. Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emj/10063690","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
慢性肾脏疾病(CKD)是一种进行性疾病,可导致肾功能衰竭,需要肾透析或移植。早期CKD经常被忽视,因为这种疾病最初是无症状的;因此,许多CKD患者在诊断时已经有症状的晚期疾病(G4-G5期)。这是一个重要的问题,因为可用于治疗慢性肾病的药物在疾病的早期阶段(G1-G3阶段)给予最有效。EMJ于2022年7月采访了两位关键意见领袖,来自加拿大温尼伯马尼托巴大学的Navdeep Tangri和来自意大利那不勒斯坎帕尼亚大学Luigi Vanvitell的Luca De Nicola,他们都在CKD患者管理方面拥有丰富的经验。专家们为正在进行的REVEAL-CKD研究提供了重要的见解,该研究旨在探索未确诊的G3期CKD的全球患病率。本文描述了迄今为止发表的REVEAL-CKD研究的主要发现及其意义。本文还讨论了提高CKD诊断的可能途径。
Findings and Implications of the REVEAL-CKD Study Investigating the Global Prevalence of Undiagnosed Stage G3 Chronic Kidney Disease
Chronic kidney disease (CKD) is a progressive condition that can lead to
kidney failure and the requirement for renal dialysis or transplantation. Early-stage
CKD is often missed because the disorder is initially asymptomatic; hence, many
patients with CKD already have symptomatic advanced disease (Stages G4–G5)
at the time of diagnosis. This is an important issue because the drugs available
for the treatment of CKD are most effective when given during the early stages of
the disease (Stages G1–G3). EMJ conducted interviews in July 2022 with two key
opinion leaders, Navdeep Tangri from the University of Manitoba, Winnipeg, Canada,
and Luca De Nicola from the University of Campania Luigi Vanvitell, Naples, Italy,
both of whom have a wealth of experience in the management of patients with CKD.
The experts provided important insights into the ongoing REVEAL-CKD study, which
was designed to explore the global prevalence of undiagnosed Stage G3 CKD. This
article describes the main findings of the REVEAL-CKD study published to date and
their implications. Possible approaches to improving the diagnosis of CKD are
also discussed.